TrialGynecologic oncology2016

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Andrea P Myers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.